Abstract
BACKGROUNDS: Anti-vascular endothelial growth factor (VEGF) therapy has been developed and recognized as an effective treatment for hepatocellular carcinoma (HCC). However, there remains a lack of noninvasive methods in precisely evaluating VEGF expression in HCC. PURPOSE: To establish a visual noninvasive model based on clinical indicators and MRI features to evaluate VEGF expression in HCC. STUDY TYPE: Retrospective. POPULATION: One hundred forty HCC patients were randomly divided into a training (N = 98) and a test cohort (N = 42). FIELD STRENGTH/SEQUENCE: 3.0 T, T2WI, T1WI including pre-contrast, dynamic, and hepatobiliary phases. ASSESSMENT: The fusion model constructed by history of smoking, albumin-to-globulin ratio (AGR) and the Radio-Tree model was visualized by a nomogram. STATISTICAL TESTS: Performances of models were assessed by receiver operating characteristic (ROC) curves. Student's t-test, Mann-Whitney U-test, chi-square test, Fisher's exact test, univariable and multivariable logistic regression analysis, DeLong's test, integrated discrimination improvement (IDI), Hosmer-Lemeshow test, and decision curve analysis were performed. P < 0.05 was considered statistically significant. RESULTS: History of smoking and AGR ≤1.5 were clinical independent risk factors of the VEGF expression. In training cohorts, values of area under the curve (AUCs) of Radio-Tree model, Clinical-Radiological (C-R) model, fusion model which combined history of smoking and AGR with Radio-Tree model were 0.821, 0.748, and 0.871. In test cohort, the fusion model showed highest AUC (0.844) than Radio-Tree and C-R models (0.819, 0.616, respectively). DeLong's test indicated that the fusion model significantly differed in performance from the C-R model in training cohort (P = 0.015) and test cohort (P = 0.007). DATA CONCLUSION: The fusion model combining history of smoking, AGR and Radio-Tree model established with ML algorithm showed the highest AUC value than others. EVIDENCE LEVEL: 4 TECHNICAL EFFICACY: Stage 2.